Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.47 |
| ▸ | CAPN1 | P07384 | 4/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.46 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.46 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.46 |
| ▸ | CTSB | P07858 | 1/20 | 0.46 |
| ▸ | NTSR2 | O95665 | 8/20 | 0.46 |
| ▸ | NTSR1 | P30989 | 8/20 | 0.46 |
| ▸ | SORT1 | Q99523 | 8/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29573140 | 0.93 | DPP4 (0.49) | KMT2AXIAPCAPN1OPRM1DPP4 | |
| SCHEMBL29349735 | 0.93 | DPP4 (0.53) | KMT2AXIAPCAPN1OPRM1DPP4 | |
| SCHEMBL30315145 | 0.92 | KMT2A (0.49) | KMT2AXIAPCAPN1OPRM1DPP4 | |
| SCHEMBL30123062 | 0.90 | OPRM1 (0.48) | XIAPOPRM1DPP4 | |
| SCHEMBL31409133 | 0.89 | CAPN1 (0.53) | KMT2ACAPN1CTSBNTSR2NTSR1 | |
| SCHEMBL29352557 | 0.89 | CAPN1 (0.50) | KMT2ACAPN1DPP4DPP8DPP9 | |
| SCHEMBL31409174 | 0.89 | CAPN1 (0.52) | KMT2AXIAPCAPN1OPRM1DPP4 | |
| SCHEMBL30638815 | 0.88 | SLC6A2 (0.53) | KMT2AXIAPCAPN1CTSBNTSR2 | |
| SCHEMBL29883844 | 0.88 | OPRM1 (0.50) | KMT2AXIAPCAPN1OPRM1DPP4 | |
| SCHEMBL29737445 | 0.88 | KMT2A (0.49) | KMT2AXIAPCAPN1OPRM1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250032477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2025-01-30 | — | — | US | claimed |
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2024-12-12 | — | — | US | claimed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | claimed |
| EP-4412656-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | claimed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | claimed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | claimed |
| EP-4619044-A1 | ANTIBODY-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | Lerchen, Hans-Georg (DE) | 2025-09-24 | — | — | EP | disclosed |
| US-20250032477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2025-01-30 | — | — | US | disclosed |
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | LERCHEN, HANS-GEORG (DE) | 2024-12-26 | — | — | US | disclosed |
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2024-12-12 | — | — | US | disclosed |
| CN-118556062-A | Compounds, pharmaceutical compositions and methods for treating, preventing or managing hyperproliferative disorders | 文赛克斯制药有限责任公司 | 2024-08-27 | — | — | CN | disclosed |
| EP-4412655-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| EP-4412656-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | Vincerx Pharma GmbH (DE) | 2024-08-14 | — | — | EP | disclosed |
| WO-2024105206-A1 | ANTIBODY-DRUG-CONJUGATES CLEAVABLE IN A TUMOR MICROENVIRONMENT | VINCERX PHARMA GMBH (DE) | 2024-05-23 | — | — | WO | disclosed |
| WO-2023057814-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
| WO-2023057812-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | VINCERX PHARMA GMBH (DE) | 2023-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240423973-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TP53, BRCA1 | KMT2A 3750/4885XIAP 314/4885CAPN1 1463/4885 |
| US-20250032477-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDERS | PCNA, TOP1, TOP2A | KMT2A 2535/4885XIAP 437/4885CAPN1 2270/4885 |
| US-20240408222-A1 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS FOR THE TREATMENT, PREVENTION, OR MANAGEMENT OF HYPERPROLIFERATIVE DISORDER | PTK2, PCNA, CDK4 | KMT2A 2446/4885XIAP 840/4885CAPN1 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.